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Abstract: AT-rich interacting domain subunit 1a (ARID1a) is an essential 
SWI/SNF component frequently mutated in human cancers. ARID1a mutations 
have also been associated with glucocorticoid resistance, potentially 
related to the well-established role of the SWI/SNF complex in 
glucocorticoid target gene regulation. Glucocorticoids are steroid 
hormones important for regulating many physiological processes through 
the activation of the glucocorticoid receptor (GR). As GR interacts 
directly with ARID1a, we hypothesized that a truncating ARID mutation 
would interfere with GR-dependent gene regulation. Using high throughput 
RNA sequencing (RNA-SEQ) we show a restricted glucocorticoid response in 
SKOV3 cells, which contain an inactivating ARID1a mutation. We also show 
a lack of GR binding at the GR-dependent regulatory site in the Period 1 
gene, which has previously been shown to require chromatin remodelling. 
Taken together, our data suggests that ARID1a may be required for 
regulation of a subset of glucocorticoid responsive genes. In the case of 
SKOV3 cells, in which ARID1a is mutated, glucocorticoid-dependent 
transcriptional regulation of these genes is significantly impaired. 
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Dear Editor 
 
 
We thank you and your reviewers for your extremely insightful and kind comments about our 
manuscript. We have attempted to address all the recommendations in our revised manuscript. 
Unfortunately, all our attempts to transfect the SKOV cells (for either reintroduction of full length 
wild type ARID1a or knock-down of the existing ARID1a) proved impossible. Therefore, we have 
shown all the data obtained from our attempts to do as the reviewer asked, in our response to 
reviewers letter (Appendices). We are confident that with our revisions in text to clarify certain 
points, and include suggested discussion, that our manuscript would be of interest to your journal’s 
audience. Therefore, we would be very pleased if you would consider our revised manuscript 
entitled ‘SKOV3 cells containing a truncated ARID1a protein have a restricted genome-wide 
response to Glucocorticoids’ for publication in Molecular and Cellular Endocrinology. We believe 
this work would still be of interest to those focused on ARID1a mutations in cancer as well as to 
glucocorticoid researchers.  
 
Yours faithfully, 
 
 
Becky Conway-Campbell 
 
Dr BL Conway-Campbell 
Research Fellow 
Dorothy Hodgkin Building 
Whitson St. Bristol, BS1 3NY 
Tel:  +44 (0)117 3313138 
Fax: +44 (0)117 3313035 
b.conway-campbell@bristol.ac.uk 
Cover Letter
1. Formally, genetic manipulation of ARID1a (either rescue by wt protein 
overexpression or knockdown of the remaining wt protein) in SKOV3 may 
strenghten the role played by the mutated ARID1a allele in the impaired GR 
response with respect to other possible alterations (including the additional 
mutations identified by RNAseq) potentially present in this particular cancer cell 
line. 
 
We agree with the reviewer that ideally we would over-express the full-length 
ARID1a in the SKOV3 cells and assess for changes in the RNAseq data. However 
several attempts have now been made to try to reintroduce the full length ARID1a 
construct back into the SKOV3 cells. Despite creating and obtaining a full length 
ARID1a construct complete with several tags and a Green fluorescent protein, 
transfecting the construct has proven incredibly difficult (See appendix A, B). 
Similarly trying to knock-down ARID1a in the SKOV3 cells has proved difficult (See 
appendix C). We now believe this to be impossible without further more invasive 
techniques such as electroporation, or methods outside our current expertise such as 
viral infection, both of which may also have many adverse effects on the cells and 
prevent us from properly deciphering the role of ARID1a. Therefore, we can only 
offer this comparison, which we have attempted to put into context appropriately in 
the manuscript.  
 
 
2. Fig 1B, how do the Authors explain the partial retention of GR in the S100 
fraction upon stimulation of SKOV3 cells ? Is ARID1a also expected to be 
involved in nuclear translocation of GR ? Should this be ARID1a-independent 
(see also point 1), this may suggest that glucocorticoid resistance of SKOV3 may 
have a heterogenous molecular basis. 
 
The fractionation methodology used for these studies is known to yield a nuclear 
extract fraction containing the high salt extractable, chromatin bound proteins, and a 
S100 fraction composed of low salt extractable, non chromatin associated nuclear 
proteins and cytoplasmic proteins (Yang et al., 1996, 1997; Liu et al., 1999a/b; Deroo 
et al., 2002; Tago et al., 2004). In our hands, ARID1a is only present in the nuclear 
(chromatin associated) fraction of the SKOV3 and HeLa cells and therefore it is not 
*Revision Notes
expected to be involved in the nuclear translocation of GR. However ARID1a may be 
involved in recruiting GR to the chromatin and this may explain why some GR is 
retained in the low salt S100 fraction. GR is not always depleted from the S100 
fraction in every cell line in the presence of Dex, so this may also be a cell specific 
trait. In order to prove GR chromatin association is dependent upon ARID1a we 
would have to first be able to overexpress or knock-down the construct (see answer to 
question 1). We would like to thank the reviewer for this comment and have amended 
the text (line number 185-188) to further clarify this.  
 
Figure 1. Data revealing the absence of ARID1a in our S100 fractions of both cell 
lines. 
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Minor 
 
3. Introduction, page 3: the last 15 lines or so, summarizing the results of the 
study, may be omitted or significantly shortened. 
 
We would like to thank the reviewer for the feedback on this section that has now 
been significantly shortened.  
 
4. Given the frequent occurrence of ARID1a mutations in cancer (perhaps also 
in patients not previously treated with glucocorticoids), do the Authors envisage 
that loss-of-function lesions, such as the one described in this study, may be only 
involved in secondary resistance to glucocorticoids or play additional roles in 
driving cancer formation (also regardless glucocorticoids exposure) ? 
 
Again we would like to thank the reviewer for these questions. It is well known and 
largely published that ARID1a is a tumour suppressor. I have now included this into 
the introduction (line number 56-58). 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A. Overexpression of a Full length ARID1a construct 
 
A pcDNA6-ARID1a construct was obtained as bacteria in an agar stab (Addgene, 
UK). Bacteria were grown and plasmid DNA was extracted using a Qiagen maxi-prep 
kit (Qiagen, UK) following the manufacturer’s instructions. SKOV3 cells were grown 
for 24 hours in normal growth medium in 10cm2 plates to 70% confluence. The media 
was changed to a reduced serum Optimem (Gibco, Life Technologies, UK) an hour 
prior to transfection. A selection of quantity ratios of DNA to Lipofectamine2000 
(Invitrogen, UK) were combined together and incubated for 5 minutes in Optimem at 
room temperature before being added to the cells (Table 1). Following an overnight 
incubation whole cell lysates were prepared for Western blotting. Anti-ARID1a 
antibodies (Bethyl Labs; A301-040A, A301-041A), a His-tag antibody (Cell 
signaling, 2365) and a loading control Beta Tubulin (Sigma, T4026) were used for 
protein detection.  
 
Table 1: Transfection ratios of DNA to Lipofectamine2000. Transfecting 
pcDNA6-ARID1a into SKOV3 cells.  
Condition  PcDNA6-ARID1a 
(673.2 μg/ml) (μl) 
Lipofectamine2000 
(μl) 
Optimem volume required 
for 1ml (μl) 
Untransfected 0 30 970 
Low DNA transfection 14 30 956 
High DNA transfection  20 30 950 
Very high DNA transfection 28 30 942 
 
No change in the detection of ARID1a protein was observed (Figure 1). Beta tubulin 
is used as a loading control for SKOV3 whole cell lysates. Similarly, no His-tagged 
protein could be detected by Western Blot using an anti-His antibody in whole cell 
lysates or nuclear extracts in these cells (data not shown). As we had no positive 
control for the antibody we were therefore unable to determine whether the construct 
had been transfected into the cells. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Western blot showing no increase in the amount of ARID1a protein in whole 
cell lysates after attempted transfection of Addgene pcDNA6-ARID1a in SKOV3 cells. 
Beta Tubulin is used as an endogenous loading control. 
 
B: Transfecting a full length ARID1a-GFPN1 construct 
 
   A fluorescent-tagged construct was considered to be beneficial in optimizing the 
transfection, in particular to aiding in the direct observation of the transfection 
efficiency during optimization. The following construct was created using a GFP-N1 
backbone vector and incorporates a HIS-TAG (Figure 2). SKOV3 cells and HeLa 
cells (used as a comparison) were grown for 24 hours in normal growth medium in 
10cm2 plates to 70% confluence. The media was replaced with reduced serum 
Optimem (Gibco, Life Technologies, UK). A variety of concentrations of DNA to 
Lipofectamine2000 (Invitrogen, UK) were used to determine the best transfection 
efficiency. ARID1a-GFPN1 DNA and Lipofectamine2000 were incubated together 
for 5 minutes in Optimem before addition to the cells. Following an overnight 
incubation cells were observed using a fluorescence microscope (Leica Biosystems, 
UK).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: GFPN1 vector and ARID1a insert from Addgene vector. A) Represents the two 
constructs, GFPN1 and pcDNA-ARID1a, which are digested and ligated to create ARID1a-
GFPN1. B) Schematic of ARID1a-GFPN1 and the restriction enzymes used to create 
construct.  
A. 
B. 
 However no fluorescence was observed using Lipofectamine2000 so other 
transfection reagents were used. K2 transfection reagent (Biontex Laboratories, UK) 
was the most successful transfection reagent used. However even using the ‘In-Cell 
1000’ to visualize transfected cells, there was no tranfection of SKOV3 cells and very 
few cells transfected in HeLa cells (Figure 3). Consistent with this, Western blotting 
of SKOV3 cells again revealed a lack of increase in the ARID1a protein levels. As 
HeLa cells are regarded as relatively easy to transfect, the likelihood of 
overexpressing ARID1a in the SKOV3 cell line seemed highly unlikely without using 
a viral infection protocol, which we did not have access to.  
 
Figure 3: ARID1a-GFPN1 transfection efficiency chart. Three full length ARID1a-GFPN1 
clones (clone 1, 3 and 9) were transfected, using K2 transfection reagent, for 24 hours in 
HeLa cells. The majority of cells, indicated by the mean bar, do not show high cell 
fluorescence intensity compared to a GFPN1 transfected control and an untransfected 
(untrans) control (with only K2 transfection reagent). The mean fluorescence was very similar 
to that of untransfected cell group. Observation of cell images also revealed very few cells 
were fluorescent and suggested only a few individual cells were transfected.  
 
 
 
C: Knock-down of ARID1a using shRNA with a pSUPER construct 
  
Four sets of double stranded RNA oligos were designed to target ARID1a gene 
expression by short hairpin RNA (shRNA) knock-down when directionally cloned 
into a carrier vector, pSUPER (Table 2). Oligos contained a unique 19-nucleotide (nt) 
sequence derived from the ARID1a mRNA transcript, which was targeted for gene 
suppression. The forward and reverse oligos were designed to anneal and be cloned 
into the pSUPER vector, between the unique BglII and XHOI sites. This design 
enables the forward oligo to be positioned downstream of the pSUPER H1 promoter’s 
TATA box. The ARID1a gene sequence and therefore the 19 nt mRNA sequence 
corresponds to the sense strand of the subsequent pSUPER produced siRNA. The 
antisense strand of the siRNA binds to this mRNA region to promote cleavage of the 
siRNA. The forward oligo also contains a 9 nt spacer sequence which separates the 19 
nt target sequence within both the sense and antisense strands.  The oligo 5’ overhang 
corresponds to a BamHI site that is compatible with the plasmid’s 3’ BglII overhang 
therefore ligation destroys the BglII site producing a higher chance of obtaining 
positive clones.  Cloning was successful and attempts were made to transfect DNA 
constructs into SKOV3 cells and HeLa cells.  
 
Table 2: RNA oligos for shRNA ARID1a knock-down.  
Target ARID1a 
Sequence  
OLIGO Design 
cgtgtgtggagaacttaga 
(7268~)*, UTR 
5’-GATCCCCcgtgtgtggagaacttagaTTCAAGAGAtctaagttctccacacacgTTTTTC-3’ 
           3’-GGGgcacacacctcttgaatctAAGTTCTCTagattcaagaggtgtgtgcAAAAAGAGCT-5’   
(BamHI)                                                                                                                     (XHOI) 
ccaacaacatggcggacaa 
(883~), ORF 
5’-GATCCCCccaacaacatggcggacaaTTCAAGAGAttgtccgccatgttgttggTTTTTC-3’ 
           3’-GGGggttgttgtaccgcctgttAAGTTCTCTaacaggcggtacaacaaccAAAAAGAGCT-5’   
(BamHI)                                                                                                                     (XHOI) 
tggcagaaggaggagactt 
(3834~)*, ORF 
5’-GATCCCCtggcagaaggaggagacttTTCAAGAGAaagtctcctccttctgccaTTTTTC-3’ 
           3’-GGGaccgtcttcctcctctgaaAAGTTCTCTttcagaggaggaagacggtAAAAAGAGCT-5’ 
(BamHI)                                                                                                                     (XHOI) 
gccaaggagagcagagtaa 
(2379~)*, ORF 
5’-GATCCCCgccaaggagagcagagtaaTTCAAGAGAttactctgctctccttggcTTTTTC-3’ 
           3’-GGGcggttcctctcgtctcattAAGTTCTCTaatgagacgagaggaaccgAAAAAGAGCT-5’ 
(BamHI)                                                                                                                     (XHOI) 
Oligos were purchased from Sigma, UK 
 
The construct DNA was incubated with Lipofectamine3000 (and Lipofectamine3000 
additional reagent) (Invitrogen, UK) for exactly 5 minutes before addition to HeLa 
and SKOV3 cells. For a control, the PSUPER vector alone was transfected in the 
same way into the cells. Unfortunately, the efficiency of the transfection was low, as 
observed under a fluorescent microscope, and failed to knock-down the 250kDa 
ARID1a protein band seen on Western blots (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Western blot showing no knock-down in ARID1a protein levels following 
transfection with several pSUPER-ARID1a shRNA clones compared to the pSUPER 
vector alone. Lamin is used as an endogenous loading control for HeLa cell nuclear extracts.   
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Abstract 20 
AT-rich interacting domain subunit 1a (ARID1a) is an essential SWI/SNF component frequently 21 
mutated in human cancers. ARID1a mutations have also been associated with glucocorticoid 22 
resistance, potentially related to the well-established role of the SWI/SNF complex in glucocorticoid 23 
target gene regulation. Glucocorticoids are steroid hormones important for regulating many 24 
physiological processes through the activation of the glucocorticoid receptor (GR). As GR interacts 25 
directly with ARID1a, we hypothesized that a truncating ARID mutation would interfere with GR-26 
dependent gene regulation. Using high throughput RNA sequencing (RNA-SEQ) we show a restricted 27 
glucocorticoid response in SKOV3 cells, which contain an inactivating ARID1a mutation. We also 28 
show a lack of GR binding at the GR-dependent regulatory site in the Period 1 gene, which has 29 
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previously been shown to require chromatin remodelling. Taken together, our data suggests that 30 
ARID1a may be required for regulation of a subset of glucocorticoid responsive genes. In the case of 31 
SKOV3 cells, in which ARID1a is mutated, glucocorticoid-dependent transcriptional regulation of 32 
these genes is significantly impaired.  33 
Keywords 34 
Glucocorticoids, Glucocorticoid Receptor, SWI/SNF, ARID1a, Transcription. 35 
Abbreviations 36 
GR – Glucocorticoid Receptor 37 
GRE – Glucocorticoid response element 38 
SWI/SNF - SWItch/Sucrose Non-Fermentable 39 
BAF – BRG1 associated factor 40 
ARID – AT-rich interaction domain 41 
FKBP5 - FK506 binding protein 5 42 
Per1 – Period 1 43 
DUSP1 – Dual specificity phosphatase 1 44 
ChIP – Chromatin Immunoprecipitation  45 
FPKM - Fragments per kilobase per million mapped reads 46 
mRNA – Messenger RNA 47  48 
1. Introduction  49 
    Glucocorticoids are among the most commonly used pharmacological agents due to their potent 50 
anti-inflammatory properties (1, 2). They are also extensively used as a cancer treatment due to 51 
their ability to induce apoptosis and promote cell cycle arrest (3, 4, 5). However despite their 52 
benefits, these drugs are often associated with several side effects (6, 7, 8, 9) and a significant 53 
proportion of patients develop glucocorticoid resistance (10, 11). ARID1a mutations have been 54 
linked to glucocorticoid resistance and are identified across a multitude of human cancers often 55 
associated with poor patient prognosis (12). ARID proteins have previously been found to be tumour 56 
suppressors and knockdown of their expression can promote cancer formation (13). ARID1a is an 57 
essential component of the ATPase driven SWItch/Sucrose NonFermentable (SWI/SNF) chromatin-58 
remodelling complex. The protein’s C-terminal has previously been reported to directly interact with 59 
GR (14, 15) (Supplementary figure 1). ARID1a interacts with AT-rich sequences within the DNA (16) 60 
potentially recruiting GR to specific glucocorticoid response elements (GREs) to regulate gene 61 
expression through dynamic mobilization of the chromatin. Determining the functional role of 62 
ARID1a in GR signalling is therefore of great importance for understanding how mutations in the 63 
SWI/SNF subunit could contribute to glucocorticoid resistance. 64 
     Glucocorticoids act through the binding of GRs located in the cell cytoplasm bound to chaperone 65 
proteins (17, 18, 19). Upon ligand binding, GR translocates to the nucleus where it binds at GREs (20, 66 
21, 22). Chromatin-remodelling by the SWI/SNF complex is a vital component of genomic GR 67 
signalling, with chromatin being dynamically opened and closed at GREs in target genes regulating 68 
the access of transcriptional machinery and RNA Polymerase II (23, 24).  The SWI/SNF complex is 69 
comprised of a single ATPase, important for driving the remodelling activities of the complex, and 70 
several associated BRG-1 associated factors including ARID1a (BAF250a) (25). ARID1a could be an 71 
important subunit of the SWI/SNF complex potentially facilitating and fine-tuning this GR mediated 72 
transcriptional regulation for a subset of GR-dependent genes (26). Therefore absence of the 73 
functional ARID1a protein may disrupt GR-dependent gene regulation and provide one possible 74 
mechanism for development of glucocorticoid resistance. 75 
     SKOV3 cells are a human ovarian cancer cell line that has been extensively used as a model to 76 
study molecular mechanisms and outcomes of a mutation in ARID1a (27, 28, 29). SKOV3 cells contain 77 
a truncating mutation of ARID1a in exon 3; a Glutamine (codon CAG) is altered to a premature stop 78 
codon (TAG) at position 586 in the amino acid sequence (28). Such a truncating mutation results in 79 
loss of the reported GR binding domain so may impact on GR-dependent gene regulation. To test 80 
this, the glucocorticoid responsiveness of the SKOV3 cells has been assessed using RNA-SEQ 81 
expression profiling over a 6 hour Dexamethasone (Dex) time course. As a technical control for our 82 
analysis pipeline, we have conducted parallel assessment of the robustly glucocorticoid responsive 83 
HeLa cell line (30, 31) known to contain a full-length functional ARID1a. 84 
 85 
2. Methods 86 
 87 
2.1 Cell culture 88 
 89 
    Human cervical cancer cell line, HeLa cells, and human ovarian adenocarcinoma, SKOV3 cells, were 90 
obtained from the European Collection of Cell Cultures (ECACC; Sigma-Aldrich), each as a frozen 91 
stock. Human HeLa cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with L-92 
glutamine and glucose (Gibco, Life Technologies, UK), 10% foetal calf serum (FCS, Invitrogen, UK) and 93 
1% penicillin/streptomycin (Gibco, Life Technologies, UK). Human SKOV3 cells were maintained in 94 
phenol red McCoy’s 5a modified medium (PAA, UK), 10% FCS (Invitrogen, UK) and 1% 95 
penicillin/streptomycin (Gibco, Life Technologies, UK). Cells were cultured in 10cm2 plates (for RNA 96 
extraction and RT-qPCR) OR 115cm2 flasks (for ChIP) and maintained in a humidified incubator (LEEC 97 
Ltd., UK) at 37oC and 5% CO2 until 70% confluent. Cultures were washed 3 times in PBS 24 hours 98 
prior to hormone addition and maintained in serum and phenol red free DMEM-F12 medium 99 
supplemented with 100 μg/ml BSA (fraction V) (GIBCO) and 10 μg/ml transferrin (Sigma). A final 100 
concentration of 100nM Dex was added to this culture medium.  101 
2.2 Nuclear fractions 102 
As previously described (32) the cells were resuspended in 300μl S1 buffer [10 mM pH 7.9 HEPES, 10 103 
mM KCl, 1.5 mM MgCl2, 0.1 mM pH 8 EDTA] supplemented with 0.5 mM dithiothreitol (DTT), 50x 104 
complete protease inhibitor (Roche, UK), 2mM NaF and 0.2mM NaVan. Samples were briefly spun at 105 
2000 x g at 4 oC and the cytoplasmic S100 fraction was removed. The nuclear pellet was resuspended 106 
in 1.2 volumes of cold S2 buffer [10 mM pH 7.9 HEPES, 400 mM NaCl, 1.5 mM MgCl2, 0.1 mM pH 8 107 
EDTA, 5% glycerol] supplemented with 2mM NaF, 0.2 mM NaVan, 0.5mM DTT and Complete 108 
protease inhibitor (Roche, UK). The pure nuclear fraction and cytoplasmic fraction were then stored 109 
at -80 oC. A bicinchoninic acid assay (Pierce, Rockford, IL) was used to determine protein 110 
concentrations. 111 
2.3 Western blotting 112 
As previously described in ref. Antibodies used were ARID1a A301-040A (Bethyl labs) and A301-041A 113 
(Bethyl labs), GR E20 (Santa Cruz, sc-1003), Anti Beta Tubulin (Sigma, cat: T4026) and Anti Lamin (Cell 114 
Signaling Technology, 2032). The membranes were washed and incubated with the appropriate 115 
secondary antibody, ECL anti-rabbit, cat: NA934V, or ECL anti-mouse, cat: NA931V (GE Healthcare, 116 
UK). Protein bands were detected using chemiluminescence; an enhanced chemiluminescence (ECL) 117 
reagent (EZ-ECL Biological Industries, USA). 118 
2.4 RNA extractions and Real time qPCR 119 
RNA was purified using membrane columns (RNAeasy minikit, Qiagen, UK) following the 120 
manufacturer’s guidelines. The RNA sample was diluted using nuclease free water and 1mg of RNA 121 
was reversed transcribed into cDNA using a cloned Avian Myeloblastosis Virus (AMV) first strand 122 
synthesis kit (Invitrogen, Life Technologies, UK) following the manufacturers guidelines.  Real-time 123 
PCR assays were performed using SYBR (Applied biosystems) and primers (see Supplementary table 124 
1). 125 
2.5 Chromatin Immunoprecipitation 126 
  After treatment, cells were fixed for 10 minutes in 1% formaldehyde, quenched with 0.125M 127 
glycine and washed with PBS. Nuclear extracts were prepared as described in 2.2, then resuspended 128 
in 6 Vol MNase digestion buffer  [50mM Tris-HCl, pH 7.5, 4mM MgCl2, 1mM CaCl2, 0.32mM sucrose, 129 
2mM NaF, 0.2mM NaVan] with 2 units of MNase (cat: N5386, Sigma, UK) per 180μg chromatin for 15 130 
minutes at 37 oC. MNase digestion was stopped with addition of 5mM EDTA pH8 on ice. The nuclear 131 
pellet was resuspended in 300μl sodium dodecyl sulfate (SDS) lysis buffer [1% SDS, 10mM EDTA, 132 
50mM Tris-HCl pH 8.1], supplemented with complete protease inhibitor (Roche Diagnostics, Burgess 133 
Hill, UK), 2mM NaF and 0.2mM NaVan. Lysates were cleared of debris by centrifugation at 16200 x g 134 
for 15 minutes at 4oC and the soluble chromatin was collected for chromatin immunoprecipitation 135 
(ChIP). For each ChIP reaction, 30μg samples were processed with H300 GR antibody (Santa Cruz sc-136 
8992) or rabbit non-immune serum (Santa Cruz sc-2027). RT-qPCR was performed using SYBR 137 
reagents (Applied Biosystems) and the following Per1 primers. 138 
Primer sequences (h, human; 5’-3’) 139 
Distal hPER1, F ACAGGACGGCTGTCGTTTTG 140 
Distal hPER1, R CGCACTTGGGAACATCATGT 141 
 142 
Distal hPER1, F TCATGTTCTCTTGGCTGGTG  (33) 143 
Distal hPER1, R GGCCCCCTTCCTACTAATCC  (33) 144 
 145 
Proximal hPER1, F CTAGTCCGAAGTGGGCTGAC (33) 146 
Proximal hPER1, R CCGGTCTTCTTGCTCGTTAC (33) 147 
 148 
Exon 19 hPER1, F GCCTTGGTGCTCCCTAACTA 149 
Exon 19 hPER1, R TCTGGAGTGCCCCATAAGGA 150 
 151 
2.6 High throughput RNA Sequencing 152 
 153 
High throughput RNA sequencing was performed (Bristol genomics facility) and the raw data was 154 
analysed using Galaxy (www.galaxyproject.org). Three lanes were uploaded for each RNA sample 155 
and for each condition an n of at least 3 were assessed. The Cuff Diff parameters included were 156 
geometric library organization, pooled dispersion estimation, 0.05 False discovery rate, Min 157 
alignment count 10, multi-read correct, bias correction and cuff-links effective length correction. 158 
Differential gene expression was calculated as fragments per kilobase per million mapped reads 159 
(FPKM) values; summed fragments of each transcript with same gene ID. After Benjamini-Hochberg 160 
false discovery correction, genes with adjusted p values less than 0.05 were considered as 161 
differentially expressed genes. 162 
 163 
3. Results 164 
3.1 Decreased ARID1a protein expression in SKOV3 cells 165 
    We have confirmed a mutation (C1756T) in exon 3 of ARID1a (Supplementary Fig 2) resulting in a 166 
premature stop codon (Q586*) in SKOV3 cells as described previously (28). Interestingly, we can 167 
detect both transcripts in the sequencing data, consistent with a heterozygous mutation.  Western 168 
blotting was used to assess whether this mutation resulted in loss of ARID1a protein (Figure 1). A 169 
strong 250kDa band was detected in the nuclear fraction of the positive control HeLa cells (Figure 170 
1A) but not detected in HeLa cells after ARID1a siRNA knockdown (Figure 1B) confirming the band to 171 
be ARID1a. As shown in Figure 1A a 250 kDa band was also detected in the nuclear fraction of SKOV3 172 
cells indicating the presence of full-length ARID1a. Using Image J Densitometry 173 
(http://imagej.nih.gov/ij) SKOV3 cells were found to express approximately 62 % of the full-length 174 
ARID1a protein expressed in HeLa cells. Taken together, the RNA-SEQ and Western blot results 175 
indicate that the ARID1a mutation in SKOV3 cells is heterozygous. ARID1a has been suggested to be 176 
a haplosufficient tumour suppressor with a large proportion of cancers containing a heterozygous 177 
ARID1a mutation (27, 34). 178 
 Finally and importantly for this study, both cell lines possess a full-length, functional GR indicated by 179 
a band detected at the expected size of 97kDa, which was detected in the nuclear fraction only after 180 
Dex treatment (Figure 1C, D). Similar GR protein levels were found for both cell lines in the absence 181 
of Dex. In contrast to the near complete depletion of GR from the S100 fraction after Dex treatment 182 
in HeLa cells, a visible GR band remains in the S100 fraction after Dex treatment in SKOV3 cells. This 183 
is highly suggestive of the presence of ‘a pool of inactive GR’ remaining after Dex treatment in the 184 
SKOV3 cells. This reflects an impairment of GR chromatin interactions or stability in SKOV3 cells 185 
potentially due to the loss of some full length ARID1a. ARID1a was not found in the S100 low salt 186 
cytoplasmic fraction for either cell line (data not shown). This is in contrary to previous suggestions 187 
that ARID1a is shuttled from the cytoplasm to the nucleus (35). As ARID1a appears to be associated 188 
with the chromatin it thereby would not be essential for GR translocation from the cytoplasm. 189 
Despite this, there was still a robust activation response detected in the SKOV3 cells, with a 190 
significant translocation of GR to the ‘active nuclear fraction’.   191  192  193  194  195  196  197  198  199  200 
Figure 1: Western blots indicating the presence and subcellular localization of ARID1a and GR in HeLa cells and SKOV3 201 
cells with or without Dex treatment. A) ARID1a protein is observed in the nuclear fraction of both cell lines. Lamin is used 202 
as an endogenous loading control specific to the nuclear extract fraction (NE). B) ARID1a is observed to be knocked down 203 
in HeLa cells using reverse transfections of a combination of four siRNAs for 48 hours. C) Western blot showing GR in HeLa 204 
cells in the nuclear extract (NE) and cytoplasm (S100) with or without Dex. The translocation of GR into the nuclear fraction 205 
upon Dex treatment indicates a functional GR protein. Beta Tubulin is used as a control specific to the cytoplasm. D) 206 
Western blot showing GR in SKOV3 cells with or without Dex in both the NE and cytoplasm (S100). An increase in GR into 207 
the nucleus upon Dex treatment indicates that GR is functional. 208  209 
 210 
3.2 Basal expression profiling characterises cell-specific differences between SKOV3 and 211 
HeLa cells  212 
   It was first important to determine cell-specific basal expression differences between the SKOV3 213 
and HeLa cells prior to assessing glucocorticoid responsiveness. Therefore, RNA-SEQ expression 214 
profiles of the two cell lines were compared in the absence of glucocorticoid (time 0hr). As expected 215 
there are several cell-specific expression differences at baseline (pre-treatment, time 0hr) as shown 216 
by the heat map, Figure 2A. By comparing these basal groups for both cell lines, 3171 genes were 217 
identified as being more highly expressed in HeLa cells compared to SKOV3 cells. Additionally, 3507 218 
genes are more highly expressed in the SKOV3 cells compared to the HeLa cells (Supplementary 219 
table 1). This is the expression profile that defines each cell line, indicating expected cell-specific 220 
differences in their respective transcriptomes. Despite the difference in protein observed from 221 
Western blotting, basal ARID1a mRNA levels are very similar in both cell lines. Basal GR mRNA levels 222 
in SKOV3 cells are approximately 3 times lower than the levels in HeLa cells. Importantly, there are 223 
large numbers of genes that are common to both cell lines (Figure 2B, C). Figure 2C shows a high 224 
correlation between basal expression values of genes with FPKM values greater than 1 for both HeLa 225 
and SKOV3 cells with a Pearson correlation coefficient of 0.86. Many commonly expressed 226 
glucocorticoid responsive genes such as GILZ (38), IRS2 and THBD (39) have similar basal expression 227 
levels. However, some largely ubiquitous genes such as Per1 and DUSP1 are expressed at lower 228 
levels in the SKOV3 cells; the basal mRNA levels are approximately 3 times lower for Per1 and 2 229 
times lower for DUSP1 compared to HeLas. Some widely expressed genes such as DKK1 (40) have 230 
much higher basal expression in the SKOV3 than in the HeLas; basal expression is approximately 14 231 
times higher in SKOV3 cells. However, it is predominantly the overall pattern of global changes after 232 
Dex treatment that is important for a comparison of the glucocorticoid responsiveness of these two 233 
cell lines.  234  235  236 
Figure 2: Basal gene expression and genes regulated by Dex in HeLa versus SKOV3 cells. A) Heat map indicating the Log10 237 
expression of genes after 0hr (control), 1hr, 3hr and 6hr Dex treatment in both HeLa and SKOV3 cells (includes all genes 238 
with a value of >1 FPKM at basal (0hr) gene expression for either cell line). Blue and Red represent lowest and highest 239 
expression levels respectively, with intermediate expression levels represented by the colour gradient indicated in the key. 240 
B) A Venn diagram to show the total number of significantly regulated Dex responsive genes, in HeLa cells compared to 241 
SKOV3 cells, that are regulated at any stage during the 1, 3 and 6 hour timecourse as determined by differential expression 242 
analysis of RNA-SEQ data as described by Trapnell and colleagues (36, 37). All genes shown are significantly differentially 243 
regulated at the P < 0.05 level and FPKM values > 1. C) Pearson correlation coefficient (r) = 0.86 and P value (p) = <0.001 244 
between genes with FPKM values > 1 at basal levels for HeLa and SKOV3 cell (in Log2). Data in red represents genes with 245 
>1.5x fold expression in SKOV3 compared to HeLa cells. Data in blue represents genes with >1.5x fold expression in HeLa 246 
compared to SKOV3 cells. A line of best fit is also shown. D, E) Volcano plot showing differentially expressed genes (of 247 
genes with basal levels FPKM values > 1) in HeLa cells (D) and SKOV3 cells (E) following 3 hours of Dex treatment. The 248 
negative Log10 transformed P values test the null hypothesis of no expression level change between basal level controls 249 
and cells with 3 hours of 100nM Dex treatment (y-axis) and are plotted against the average Log2 fold changes in expression 250 
(x-axis). Data for genes that were not differentially expressed are plotted in black. Data for genes that were differentially 251 
expressed (as determined by Benjamini-Hochberg correction analysis with FDR = 0.05 for RNA-SEQ) are plotted in blue (P < 252 
0.05), green (P < 0.01) and red (P < 0.001). F, G, H, I) Venn diagram analysis shows overall numbers of regulated genes over 253 
the timecourse in each cell line. Significant gene induction (F, G) and repression (H, I) in HeLa (F, H) and SKOV3 cells (G, I) 254 
determined by differential expression analysis of RNA-SEQ data (36, 37; using Benjamini-Hochberg correction FDR=0.05), 255 
following Dex treatment of 1, 3 and 6 hours compared to 0 hour control. All genes shown are significantly differentially 256 
regulated at the P < 0.05 level and FPKM values > 1. 257 
 258 
3.3 SKOV3 Cells Exhibit a Restricted Genome-Wide transcriptional response to 259 
Glucocorticoids 260 
Visualisation of global changes in gene expression over the timecourse of Dex treatment (Figure 2A) 261 
revealed striking differences between the two cell lines, which is further shown quantitatively in the 262 
Venn Diagram analysis of Dex-regulated genes (Figure 2B). Figure 2D and 2E compares the 263 
glucocorticoid responsiveness of genes common to both cell lines and demonstrates greater fold 264 
change, seen as both higher inductions (Log2 fold change > 0) and greater repressions (Log2 fold 265 
change < 0) of a larger number of genes in HeLa cells (Figure 2D) compared to SKOV3 cells (Figure 266 
2E). The total number of induced or repressed genes, over the full timecourse, for both cell lines is 267 
shown in by Venn diagram (Figure 2F, G, H, I).  Over the full Dex timecourse, a total of 101 268 
transcripts were upregulated in SKOV3 cells compared to 570 in HeLa cells (Figure 2 F, G). A total of 269 
49 transcripts were downregulated by Dex in the SKOV3 cells compared to 350 in the HeLa cells 270 
(Figure 2 H, I).  271 
Real-time quantitative polymerase chain reaction (qPCR) was used to validate differential regulation 272 
of a selection of targets identified in the RNA-SEQ analysis. Differential regulation of the well-known 273 
Dex-regulated genes Per1, FKBP5, BIRC3, DUSP1, SLIT2, FR-alpha and SLIT3 is shown in Figures 3B, 274 
and 3C. Both cell lines had a significant induction of Per1 by 6 hours of Dex treatment, although 275 
induction was far more rapid in the HeLa cells reaching significant upregulation at 1hour (Figure 3A). 276 
DUSP1 was induced by 1 hour in HeLa cells but only showed a non-significant trend towards 277 
induction by 6 hours of Dex treatment in the SKOV3 cells. BIRC3 and FKBP5 were significantly 278 
induced in HeLa cells (Figure 3A) but not in SKOV3 cells, which is comparable to the RNA-SEQ data. 279 
FR-alpha, which is highly Dex inducible in some cancer cell lines, is not regulated by Dex in SKOV3 280 
cells (Figure 3B) (41). SLIT2 and SLIT3 were not regulated by GR in SKOV3 cells, despite being 281 
repressed by glucocorticoids in the majority of ovarian cell lines (31) (Figure 3B). All these results 282 
were consistent with the RNA-SEQ differential expression data and provided supporting evidence for 283 
impaired GR-dependent gene regulation in SKOV3 cells. Overall RT-qPCR analysis confirmed the 284 
restricted transcriptional response shown by the sequencing data. 285 
3.4 SKOV3 Cells Show a Delayed Transcriptional Response to Dexamethasone  286 
  RNA-SEQ analysis revealed fewer genes to be responsive to Dex following 1 hour of treatment in 287 
the SKOV3 cells compared to the HeLa cells. Only 11 genes were induced and 7 genes repressed 288 
after 1 hour of Dex treatment in SKOV3 cells. In comparison, 94 genes were induced and 17 289 
repressed after 1 hour Dex treatment in HeLa cells (Figure 2 F, G). In HeLa cells, 72 genes (12.6% of 290 
all Dex inducible genes in HeLa cells) are induced throughout the Dex timecourse. A further 182 291 
genes (31.9% of all Dex inducible genes in HeLa cells) were induced at both the 3 hour and 6 hour 292 
time points. Interestingly, in contrast to HeLa cells no genes are induced throughout the entire 293 
timecourse in SKOV3 cells. However, 21 genes were continually induced from the 3 hour timepoint 294 
(only 20.8% of all SKOV3 Dex inducible genes). Furthermore, some of the genes regulated in 295 
common between the two cells types exhibited a delayed induction in the SKOV3 compared to the 296 
Hela cells. For Per1, gene induction was more gradual and progressed at each time interval in the 297 
SKOV3 cells in comparison to the control HeLa cells where induction reached a significant increase at 298 
the earlier 1 hour time point (Figure 3 A). A few other highly Dex inducible genes, DUSP1, GILZ, 299 
CEBPD, NFKBIA, DKK1 and ZFP36, similarly to Per1, are induced from 1 hour of Dex treatment in 300 
HeLa cells but induction in SKOV3 cells is only observed at 3 hours of Dex treatment. These genes are 301 
positioned in the central area of the Venn diagrams in Figure 3C and 3D showing genes induced by 3 302 
hours and 6 hours of Dex treatment in SKOV3 cells respectively, compared to genes induced from 1 303 
hour of Dex treatment in HeLa cells. These two diagrams indicate the genes that are regulated in 304 
both cell lines from 3 hours of Dex treatment. Despite a delay in the transcriptional response of Dex 305 
inducible genes in SKOV3 cells there is no observed delay in Dex repressed genes. Previous studies 306 
have shown that the majority of downregulated genes are repressed less rapidly than the majority of 307 
upregulated genes are induced (42, 43). Therefore we cannot rule out that repression may occur at a 308 
later timepoint. Despite this, consistent with a delay in repression fewer genes are repressed in 309 
SKOV3 cells, 49 genes, in comparison to HeLa cells, 350 genes over the 6 hour timecourse. 310 
Conversely, in contrast to induced genes the vast majority of repressed genes have previously been 311 
shown to remain unaffected by the ablation of the SWI/SNF function (26). Overall this apparent loss 312 
of ‘rapid’ regulation of several genes in SKOV3 cells compared to HeLa cells and may suggest either a 313 
delay in GR binding, or a delay in the recruitment of required transcriptional components necessary 314 
for GR-dependent gene regulation. This could include binding of co-regulators such as the SWI/SNF 315 
complex or any factors of the transcriptional preinitiation complex including RNA Polymerase II. 316 
 317 
3.5 Loss of Prolonged Glucocorticoid gene regulation in SKOV3 cells 318 
RNA-SEQ data revealed loss of induction of a large number of glucocorticoid responsive genes by 6 319 
hours of Dex treatment in SKOV3 cells. This is in stark contrast to HeLa cells, where a large 320 
proportion of genes showed prolonged induction that remained upregulated at 6 hours (Figure 2 F, 321 
G). Only 20.8% of genes remained significantly upregulated from 3 hours of Dex treatment in SKOV3 322 
cells compared to 44.6% of Dex inducible genes in HeLa cells. In SKOV3 cells, 90.9% of genes (10/11) 323 
induced following 1 hour of Dex treatment returned to baseline expression levels throughout the 324 
timecourse. Additionally 62.5% of genes (35/56) induced following 3 hours of Dex treatment showed 325 
loss of induction by 6 hours of treatment. In contrast, in HeLa cells, only 13.8% of genes (13/94) 326 
induced by 1 hour of Dex treatment showed loss of induction across the timecourse. Only 30% of 327 
genes (109/393) induced following 3 hours of Dex treatment returned to basal levels by 6 hours of 328 
treatment. In SKOV3 cells, 59% of Dex repressed genes do not remain repressed by 6 hours of Dex 329 
treatment. This is a large proportion of Dex repressed genes when in comparison 87.7% of repressed 330 
genes in HeLa cells remain downregulated at 6 hours of Dex treatment. The loss of prolonged Dex 331 
regulation of genes in SKOV3 cells throughout the timecourse may indicate a loss of GR-dependent 332 
gene regulation caused by the loss of ARID1a protein 333 
 334 
 335  336 
B. 
C. D. 
A. 
 337 
Figure 3. Pattern of gene induction for common glucocorticoid responsive genes in SKOV3 cells compared to HeLa cells.  338 
A - B) Fold change in mRNA expression normalised to β glucuronidase for SKOV3 cells (Purple) and HeLa cells (Blue) during 339 
a Dex treatment timecourse. Data is represented at mean +/- Standard Error Mean (SEM).  A) In both HeLa and SKOV3 cells 340 
the mRNA expression of Per1 is significantly increased following 6 hours of Dex treatment. In HeLa cells the mRNA 341 
expression of Per1 is also significantly increased at times 0, 1 and 3 hours. DUSP1 is significantly induced in HeLa cells at all 342 
timepoints of Dex treatment but only shows a trend towards induction over the timecourse in SKOV3 cells. Induction of 343 
BIRC3 and FKBP5 are also shown in HeLa cells but not in SKOV3 cells. For B) Two-way ANOVA with Dunnett’s post-hoc test 344 
with all comparisons to the time 0 control were used and statistical significance indicated at P < 0.05 level (*), P < 0.01 (**), 345 
P < 0.001 (***), P < 0.0001 (****). C) Lack of regulation of commonly reported, ovarian specific, Dex regulated genes in 346 
SKOV3 cells FR-alpha, SLIT2 and SLIT3. Data is represented at mean +/- SEM. One-way ANOVA with Dunnett’s post-hoc test 347 
was used, with all comparisons to the time 0 hour control. No statistically significant differences were detected. C) Venn 348 
diagram analysis shows number of genes induced by 3 hour Dex treatment in SKOV3 cells compared to genes induced by 349 
Dex in HeLa cells at 1, 3 and 6 hours. D) Genes induced by 6 hour Dex treatment in SKOV3 cells compared to genes induced 350 
by Dex in HeLa cells at 1, 3 and 6 hours. For C) and D) all genes shown are significantly differentially regulated at the P < 351 
0.05 level following Benjamini-Hochberg correction and FPKM values > 1.  352 
 353 
 354 
 355 
 356 
 357 
Figure 4:  GR binding at the Per1 proximal and distal GREs determined by ChIP studies. A) Schematic of the human Per1 358 
gene and the position of the distal and proximal GRE sites. B) GR binding at the Distal and Proximal GREs in HeLa cells. C) 359 
GR binding at the Distal and Proximal GREs in SKOV3 cells. One way ANOVA with Dunnett’s Post-hoc Test *** P<0.001. 360 
 361 
 362 
 363 
3.6 SKOV3 cells have Decreased GR binding at a Chromatin Remodelling inducible GRE in 364 
Per1 365 
 366 
   Per1 was chosen as a candidate gene to assess GR binding. Per1 contains two GR binding sites, the 367 
first more distal site is a glucocorticoid and DNase1 hypersensitive GRE whereas the second proximal 368 
site is an inducible GRE site requiring chromatin remodelling (Figure 4 A) (44). Therefore, it provided 369 
a model for observing GR binding at a pre-accessible GR binding region, and at a site that is thought 370 
to require GR to mediate further chromatin remodelling potentially through the recruitment of the 371 
SWI/SNF complex. As both qPCR and RNA-SEQ suggested a delay in Per1 gene induction in response 372 
to Dex and an overall lower level of Per1 expression and induction in SKOV3 cells compared to HeLa 373 
cells it was important to determine whether these changes were due to the identified ARID1a 374 
mutation. 375 
    GR binding at the Per1 distal GRE region increased significantly following a 30 minute treatment 376 
with Dex in both cell lines compared to untreated controls (Figure 4 B, C). It should be noted that GR 377 
binding at the distal GRE was lower in the SKOV3 cells compared to that in the HeLa cells. At the 378 
proximal Per1 GRE region (within intron 1) GR binding increased following 30 minutes Dex treatment 379 
in HeLa cells but not in SKOV3 cells (Figure 4 B, C). This loss of GR binding at the proximal site may 380 
suggest decreased chromatin accessibility at this site. This could suggest that ARID1a is important for 381 
promoting the accessibility of this site for GR binding. This is potentially a mechanism for pre-setting 382 
the chromatin architecture prior to glucocorticoid treatment by primary chromatin remodelling. 383 
Alternatively this proximal GRE may not be accessible for GR binding in SKOV3 cells and may be pre-384 
set by other mechanisms to be inaccessible to GR binding. This result becomes difficult to interpret 385 
with confidence in light of the lower GR binding result at the distal site in the SKOV3 cells relative to 386 
the HeLa cells.  387 
 388 
3.7 Other gene mutations and loss of RNA expression detected in human SKOV3 cells 389 
 390 
   In addition to confirming the expected C to T mutation, which alters a Glutamine (codon CAG) to a 391 
premature stop codon (TAG) at position 586 in the amino acid sequence, identified in 32% of 392 
transcripts in SKOV3 cells (Supplementary Figure 2). Our RNA-SEQ data also confirmed a truncating 393 
mutation in exon 24 of BAF155 (SMARCC1) (45) (Supplementary Figure 3) and a mutation in PIK3CA 394 
(28) in which a Histidine (CAT) is changed to an Arginine (CGT) in 45% of transcripts (Supplementary 395 
Figure 4). Another important interaction of the ARID1a protein is the direct binding of the protein to 396 
the cell cycle regulator P53 (46). However RNA-SEQ data revealed negligible P53 expression in 397 
SKOV3 cells, which is in contrast to HeLa cells.  398 
 399 
4. Discussion  400 
 401 
      Previously luciferase reporter assays have been used to suggest ARID1a is important for GR 402 
activity (15). Here we provide evidence of a cell line with an ARID1a mutation with a restricted 403 
glucocorticoid response. Notably, SKOV3 cells possess a largely restricted GR-dependent 404 
transcriptional response following Dex treatment when compared to HeLa cells. There is also an 405 
apparent delay in transcriptional regulation as well as a marked loss of transcriptional regulation of 406 
GR-dependent genes over a 6 hour Dex timecourse in SKOV3 cells, which contrasts the dynamic and 407 
robust transcriptional response observed in HeLa cells. ChIP assays assessing GR binding at 408 
regulatory sites of the Per1 gene reveals a loss of GR binding at the proximal inducible GRE 409 
containing site in the SKOV3 cells despite significant binding at this site in HeLa cells. This could 410 
suggest that ARID1a is required to pre-set the accessibility of this GRE for GR binding. Although there 411 
are significant differences between the RNA transcriptional responses and GR binding to Dex 412 
treatment between these two cells, which could indicate differences due to the presence of a 413 
mutated ARID1a, these may also be due to inherent differences in cell type and related to differing 414 
cellular functions.     415 
 416 
Multiple mutations identified in SKOV3 cells 417 
 418 
Notably, the SKOV3 cell line has been widely used to study ARID1a (27-29), however the findings 419 
emerging from our genome-wide study now reveal these cells to be a less than ideal model for this 420 
purpose. In fact, several other mutations and loss of proteins have been observed in this cell line. It 421 
is also largely recognised that cell lines containing an ARID1a mutation do also co-occur with other 422 
gene mutations. Therefore loss of ARID1a alone may not result in such large-scale loss of 423 
glucocorticoid responsiveness and may be a result of several mutations. Recent studies have shown 424 
that the addition of a PIK3CA mutation as well as an ARID1a mutation can help promote tumour 425 
formation in ovarian cancer cells (47). PIK3CA encodes the catalytic subunit of PI-3K and mutations 426 
that co-occur with ARID1a often lead to increased PI-3K, and subsequently AKT, activity (47-49). PI-427 
3K is also known to interact with GR (50). Therefore the PIK3CA mutation in SKOV3 cells may 428 
interfere with PI-3K-GR interactions and could be a reason for altered GR mediated gene regulation 429 
in this cell line. BAF 155, another subunit of the SWI/SNF complex, has also been shown to have a 430 
truncating mutation (51). Although BAF57 and ARID1a (BAF 250) have been predicted to be the main 431 
mediators of an interaction of GR with the SWI/SNF complex using Protein interactions by structural 432 
matching (PRISM) techniques (52), other BAF subunits may also be important for this interaction. 433 
BAF155 was shown to be critical for subunit associations within the SWI/SNF complex (52), therefore 434 
a mutation in BAF155 may alter interactions between other subunits such as BAF57 and ARID1a 435 
within the complex. Interestingly deletion of the C-terminal of BAF155 has been shown to disrupt 436 
the ability of this subunit to regulate the stability of BAF57 (51, 52). Therefore the restrictive GR 437 
gene response to Dex treatment in SKOV3 cells may be due to loss of BAF57 from the SWI/SNF 438 
complex, which is important for an interaction of the complex with GR. P53 is another important 439 
factor known to directly interact with ARID1a (46) and it is now widely recognized that SKOV3 cells 440 
are P53-negative, which again is supported by our RNA-SEQ data. GR-dependent cell cycle arrest can 441 
often require P53 (53-55) and loss of P53 may impact upon regulation of a specific subset of GR-442 
dependent genes. Therefore the differences in GR-dependent gene regulation observed may result 443 
from any combination of these mutations. Further studies assessing the impact of loss of other 444 
factors alongside loss of ARID1a may therefore be useful in assessing whether an impact on GR gene 445 
regulation occurs through a combination of mutations that frequently occur following ARID1a 446 
mutations observed in cancer. 447 
 448 
Truncated ARID1a protein  449 
 450 
     Another factor which could contribute to the loss of glucocorticoid responsiveness is the potential 451 
presence of small truncated ARID1a protein of the first 585 amino acids of the N-terminal that may 452 
still be present in SKOV3 cells alongside the full-length ARID1a protein. There is a lack of evidence on 453 
the role of the ARID1a-NTD but previous studies have suggested it is required for GR activation and 454 
overexpression of the ARID1a-CTD using luciferase reporter assays results in loss of GR activity (15). 455 
An LXXLL motif has however been identified in the ARID1a-NTD (295-299 amino acids) (56), which 456 
may be important in binding coactivators of GR regulation. One previous study overexpressed LXXLL 457 
containing peptides that interact with ER (57). They showed that if these peptides mimic the 458 
interactions between the receptor and endogenous co-factors they can function in a dominant 459 
negative manner to disrupt interactions and prevent transcription (57). Therefore, the 460 
overexpression of such a small truncated ARID1a N-terminal protein containing an LXXLL may act as 461 
a dominant negative and interfere with the function of GR or other NRs that require interactions 462 
with specific cofactors. The presence of a small N-terminal LXXLL containing inactive ARID1a protein 463 
could potentially bind to and sequester certain co-factors thereby interfering with GR-dependent 464 
gene regulation in SKOV3 cells. Future investigation may be aimed at further determining whether 465 
the ARID1a-NTD is translated and its role in GR-dependent gene regulation by studying the effect of 466 
overexpression of this domain in an ovarian cell line without an ARID1a mutation.   467 
 468 
Summary 469 
 470 
Despite the many caveats of the SKOV3 cell model, our genome-wide study has revealed a globally 471 
restricted transcriptional profile of GR regulated genes in these cells. This finding has potentially 472 
highlighted a functional role for ARID1a and the SWI/SNF complex in modifying the chromatin 473 
landscape for regulation of large numbers of GR regulated genes. Importantly, our study has lead to 474 
a potential mechanism to further explore in the clinical problem of glucocorticoid resistance, as 475 
ARID1a mutations have also been linked to glucocorticoid resistance in Leukaemia patients (12). 476 
Therefore further studies into ARID1a could subsequently identify subsets of cancer patients, which 477 
are likely to develop glucocorticoid resistance and could lead to identification of new therapeutic 478 
targets for these patients.  479 
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Highlights  
x SKOV3 cells have a truncated ARID1a 
x SKOV3 cells exhibit a highly restrictive response to glucocorticoids 
x We have identified impaired GR binding at a chromatin remodelling inducible site in the highly inducible glucocorticoid target gene, Per1. 
x Consistent with reduced GR binding, Per1 shows an impaired and delayed transcriptional induction. 
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